Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

th migraine. An innovative, two-stage, adaptive dose-ranging design formulated through computer simulation was used to facilitate optimal dose selection.

A total of 420 adult patients who experienced migraine attacks, as defined by the International Headache Society criteria, were randomized (330 took drug) to treat a moderate or severe migraine attack with MK-0974 given orally at doses of 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 600 mg, or rizatriptan 10 mg, or placebo. Patients enrolled were primarily female (89 percent) with an average age of 41 years. Most treated headaches were moderate in baseline severity and did not have aura.

The first stage of the study evaluated all doses of MK-0974 with rizatriptan and placebo. When a preset number of migraine attacks were treated, an interim efficacy analysis was conducted resulting in dropping the four lowest doses of MK-0974 based on a pre-specified algorithm. The second stage of the study continued with randomization of patients to MK-0974 300 mg, 400 mg or 600 mg or to rizatriptan 10 mg or placebo.

Overall treatment effect was analyzed by comparing the average response of the MK-0974 treatment groups (300 mg, 400 mg and 600 mg) to the response observed in the placebo group. The study was not powered to detect differences between the individual doses of MK-0974 or between MK-0974 doses and rizatriptan.

Study results

For the primary endpoint, the overall treatment effect of MK-0974 in relieving migraine pain (reduction from severe or moderate to mild or none) two hours after dosing was significant compared to placebo (p=0.015). The proportion of patients reporting pain relief at two hours for those treated with MK-0974 was 68.1 percent (300 mg; n=38), 48.2 percent (400 mg; n=45) and 67.5 percent (600 mg, n=40); and 69.5 percent for rizatriptan (n=34) compared to 46.3 percent for placebo (n=115).

A similar pattern was observed for secondary measures in which the overall
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:9/30/2014)... Protecting the health and safety of Canadians is our government,s highest ... and tools at its disposal to help ensure that the drugs ... To that end, Health Canada has ... Canada of all drug products from three plants in ... , Apotex Pharmachem India Pvt Ltd , Apotex Research Private ...
(Date:9/30/2014)... MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... Scientific Officer, will present at the Stem Cell Meeting ... October 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor Pharmaceuticals, ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. ... overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research ... information on the current therapeutic developmental pipeline of ... various stages, therapeutics assessment by drug target, mechanism ...
Breaking Medicine Technology:Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3
...  Qforma, the leading provider of healthcare analytics and predictive ... appointment of Ian McGuinness to the position of Vice ... to welcome Ian to our team as we continue ... the pharmaceutical business," said Al Reicheg, Chief Commercial Officer ...
... PRUSSIA, Pa., Dec. 19, 2011  Medical Alarm Concepts ... first fully-monitored medical alarm system that allows you ... today announced its plans to promote the MediPendant™ ... for Costco and its members. ...
Cached Medicine Technology:Qforma Appoints Ian McGuinness as Vice President, Business Development 2Medical Alarm Concepts™ Chosen as a Strategic Alliance Partner with Costco Warehouse Clubs 2
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new ... retired couples. , Senior citizens can purchase a ... their loved ones. A joint policy is cheaper, but ... away. , Life insurance can be used to ... even be purchased online, as the application process is ...
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... Calif., Jan. 15 Abaxis, Inc.,(Nasdaq: ABAX ... systems, announced today that Clint Severson, CEO and,President, ... Company Emerging,Growth Conference on Wednesday, January 23, 2008 ... at The Ritz-Carlton, Palm Beach Florida., About ...
... incidence of liver cancer continues to grow-- fueled in large ... too does the need for tests to help diagnose the ... in the January 15 issue of Clinical Cancer Research demonstrates ... more accurate than traditional biomarkers in distinguishing liver cancer patients ...
... 14 Access,Pharmaceuticals, Inc. (OTC Bulletin Board: ... pharmaceutical company focused on bringing,proprietary medicines to ... of a,definitive licensing agreement under which RHEI, ... penetrating large volume hospitals, will,market Access,s proprietary ...
... MINRAD,International, Inc. (Amex: BUF ) today announced the ... Jr. as the new Chief,Financial Officer and Executive Vice ... from Hardinge, Inc., where he has been the,Chief Financial ... he served as the Chief Financial Officer and Treasurer ...
... American Physical Therapy Association Sponsors National Toll-Free,Hotline Addressing Ways ... ALEXANDRIA, Va., Jan. 14 Falls are,prevalent, dangerous, and ... nearly one in two seniors over age 80, will ... consequences.* As our nation,s population,ages, the rate of falls ...
... 14 The Lake Forest Hospital,Foundation board of directors ... create a new health care system for northeastern Illinois,and ... by a,combination of both hospital boards and would bring ... consumer ranked hospitals in,Lake County.*, As part of ...
Cached Medicine News:Health News:Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer 2Health News:Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer 3Health News:Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries 2Health News:Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries 3Health News:MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP 2Health News:MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP 3Health News:Physical Therapist Intervention for Balance Impairments May Help Reduce Risk of Falling 2Health News:Physical Therapist Intervention for Balance Impairments May Help Reduce Risk of Falling 3Health News:Physical Therapist Intervention for Balance Impairments May Help Reduce Risk of Falling 4Health News:Lake Forest Hospital Proposes a New Health Care System in Lake County 2
... The Vasotrax is an ... pressure and heart rate non-invasively, ... fact, significantly more accurate than ... On a full battery charge, ...
... are heterodimeric proteins that suppress the secretion ... pituitary. Inhibin consists of two distinct chains, ... Inhibin A consists of the alpha-subunit and ... and betaB-subunit. Only the dimeric forms of ...
... (IGF-II) is a 7.5 kDa peptide which is ... to have mitogenic and metabolic actions involved in ... by binding to target cell receptors. IGF-II binds ... receptor, a monomeric protein which also serves as ...
... Pregnancy-associated plasma protein A (PAPP-A) is ... is produced in high concentrations by ... into the maternal circulation in increasing ... PAPP-A is not specific to pregnancy ...
Medicine Products: